
    
      To observe the beneficial population and adverse reactions of anlotinib hydrochloride
      combined with pd-1 in the treatment of patients with advanced solid tumor, and to explore the
      safe and effective drug treatment dose in the combined program, so that more patients with
      advanced tumor with poor prognosis can benefit from the combined program
    
  